Kaiser FluMist Safety Data Analysis To Be Submitted To FDA By Year-End
Executive Summary
Aviron expects to submit to FDA the full analysis of a FluMist pediatric safety study conducted at Kaiser Permanente outpatient clinics by the end of the year.
You may also be interested in...
FluMist Initial Indication May Exclude Patients Under Age Five
The initial label for MedImmune/Wyeth's intranasal influenza vaccine FluMist might not include an indication for children under age five
FluMist Initial Indication May Exclude Patients Under Age Five
The initial label for MedImmune/Wyeth's intranasal influenza vaccine FluMist might not include an indication for children under age five
Medimmune FluMist Indication Could Exclude Patients With Asthma
MedImmune could carve out a subpopulation of FluMist patients who suffer from wheezing and asthma from the proposed indication for the intranasal vaccine, the company said following receipt of a complete response letter from FDA